进餐艾塞那肽.PPTVIP

CITATION Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-2348. SEE pg 2344 Figure 7-B (for slide data); pg 2335 “Study design” (for background information) DISCUSSION Mean rates of nocturnal hypoglycaemia (episodes/patient-year (95% CI) were significantly less in exenatide-treated patients compared with glargine-treated patients (p.001) Sulphonylurea (SFU)-treated patients had similar rates of nocturnal hypoglycaemia In metformin (MET)-treated patients, exenatide was associated with a lower rate of nocturnal hypoglycaemia compared with insulin glargine-treated patients (p.01) STUDY H8O-MC-GWAO BACKGROUND Randomised, open-label, 2-period crossover noninferiority study of patients with type 2 diabetes previously uncontrolled with MET or an SFU. Exenatide and insulin glargine treatments were administered for 16 weeks each and prestudy dose of MET or SFU was continued. Exenatide was administered twice daily as subcutaneous injection, 60 min before AM and PM meals at 5 μg for first 4 weeks, 10 μg exenatide after 4 weeks. Once-daily insulin glargine treatment was initiated at 10 IU, and was increased weekly by 8, 6, 4, or 2 IU daily if the mean fasting serum glucose (FSG) level on two consecutive days was 10 mmol/L, 7.8 to 10 mmol/L, 6.7 to 7.8 mmol/L, or 5.6 to 6.7 mmol/L, respectively. However, if the mean FSG level was less than 4 mmol/L at any time during the previous week, the insulin glargine dose was not adjusted. DISCUSSION Summarise all points DISCUSSION Summarise all points * HbA1c control Exenatide provides sustained HbA1c control Changes in body weight Treatment with exenatide may have a secondary benefit of weight loss Risk of hypoglycaemia Exenatide is associated with a low risk of hypo